Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
×

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF| NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $5.41 | Change: $-0.13 | %Change: -2.35%
Volume: 656 | Day High/Low: 5.41/5.35 | 52 Week High/Low: 10.36/3.50
View modes: 
1 star

RE:EBITDA -is-bs-earnings

With no debt, modest depreciation, and adequate tax losses, Ebitda and net earnings for Nuvo are almost the same. Ebitda then becomes almost pure and unencumbered cash flows. Net earnings can...read more
0 stars

EBITDA -is-bs-earnings

EBITDA is a very misleading metric.  Bottom line, what matters are net earnings. http://www.forbes.com/sites/brentbeshore/2014/11/13/ebitda-is-bs-earnings/  rate and reply
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

Not sure how anybody is making money, stock has been going down consistently since he started pumping NRI as a $ 10 stock trading at $ 6. I think NRI will go up to $ 10 in a couple of years, which is...read more
1 star

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

The only informed person has to be the rock and he's probabily laughing all the way to the bank. Like they say, it's who you know, not what you know.  rate and reply
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

There is nothing worse than the informed (2 CEO's) misinforming the uninformed (shareholders) for the past 10 years that they are looking for ways to imporve shareholder value.  rate and reply
2 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

Is Horizon making big money on P2 sales? That cant be answered directly, as margins are not reported by drug. But, in Q2 total operating expenses were 83.5 % of sales. Sales and marketing alone...read more
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

Margins are simply formulated by the P/L report . No ifs...ands...or white out  about it .  rate and reply
2 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

Again, you are being distortionary with your statistics. Cost of sales of $2.9 million in Q2 was $1.7 million . The net margin was 40%. This net margin will increase as volumes produced. To quote...read more
0 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

Consultant99, thank you very much for the effort you put in your analysis and the time you spend on this forum. Are you advocating to hold and buy in the future?   I was very interested in buying...read more
0 stars

RE:RE:RE:RE:RE:RE:New Presntation

Thank you!  Great post.  I have been looking at NRI from a value perspective.  I am still on the sidelines on this one.  The earnings seems to have dropped a fair amount! consultant99 wrote: Alright...read more
5 stars

RE:RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

Gross margin on product sales for the six months ended June 30, 2015 increased to $2.4 million or 35%. TPT had a net loss in Q2 (on a segmented basis) of $(2.119) million and YTD $(1.1) million The...read more
1 star

RE:RE:RE:RE:RE:RE:RE:RE:New Presntation

While I dont disagree with some of your points,I do think that your statement of razor thin manufacturing margins is grossly in error. After accounting for its share of all operating expenses, net...read more
1 star

new base

at $ 5.25 - $ 5.30. Should hover around here for the next few quarters, expect  $ 6.00 by year end if Q3 shows better than Q2, which was an absolute disaster for shareholders. Good luck out there.  rate and reply
3.5 stars

RE:RE:RE:RE:RE:RE:RE:New Presntation

Well not only did we give up any "unexpected" upside but by selling the drug outright there was no minimum guaranteed volume either. To the latter point thankfully Horizon is not MNK but there were no...read more
1.5 stars

Annual Market Potential in US of $3.5 billion

Topica has exclusive rights to Luliconazole for onychomycosis in the Americas and Europe, and currently holds 5 patents covering composition of matter, method of use, and formulation of the 10...read more
2.5 stars

RE:RE:RE:RE:RE:RE:New Presntation

I've been away for a while, obviously. If it is lack of foresight, that the deal did not include a clause for reevaluation of the sale price if revenues exceeded threshold levels; then this doesn't...read more
0 stars

RE:RE:RE:Take a break guys

Terbinafine is in preclinical stage according to the company website - under pipeline.  rate and reply
0 stars

RE:RE:Take a break guys

might be mistaken but they were sued using  that formulation . and they went back to the drawing board after that.  rate and reply
0 stars

RE:Take a break guys

Phase I/II trials of Penecure were approved by both Health Canada and FDA just before the dissident shareholders took over the company. Does anyone know (remember) if these trials were ever conducted...read more
5 stars

RE:RE:RE:RE:Today's News

DMSO is the penetrant (Dimethyl sulfoxide). Diclofenac sodium is the active anti-inflammatory ingredient. However, it is debatable which of the two is the more effective anti-inflammatory as DMSO on...read more